Close Menu

A*Star

The company, established as a merger between A*STAR MedTech spin-off MiRXES and venture capital firm Venturecraft, has developed a blood test for early-stage stomach cancer.

The partners are aiming to generate proteomic and phosphoproteomic data that they can include in Indivumed's global cancer database.

Researchers from A*Star and elsewhere have implicated a recessive mutation in CAMK2A in a neurodevelopmental disorder affecting a pair of siblings.

The Singaporean firm already offers cell-free NIPT testing through its iGene Laboratory and sells a kit to test ovarian cysts for malignancy.

The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.

The technology relates to the isolation and genetic analysis of circulating fetal cells from maternal blood.

The first assay to be developed under the new five-year strategic partnership is a solid biopsy breast cancer assay designed to guide drug selection.

Each panel that the collaborators develop is expected to be highly multiplexed and syndromic, addressing clinically important infectious diseases in Asia.

GUSTO study researchers said maternal lifestyle, fetal genetic, and fetal epigenetic factors affect birth weight and early childhood adiposity.

While gain-of-function mutations lead to congenital arhinia, inactivating mutations lead to an adult-onset muscular dystrophy, the researchers reported.

Pages

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.